PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN
Therapeutic methods are disclosed herein.
1 .- 11 . (canceled)
12 . A method of treating keratoconjunctivitis sicca, the method comprising the step of administering an ophthalmically acceptable emulsion comprising cyclosporin A to the mammal, wherein the keratoconjunctivitis sicca is associated with the use of a therapeutically active agent comprising zalcitabine.
13 . The method of claim 12 , wherein the ophthalmically acceptable emulsion comprises cyclosporin A at a concentration of about 0.05%.
14 . The method of claim 13 , wherein the ophthalmically acceptable emulsion further comprises castor oil, polysorbate 80, and high molecular weight co-polymers of acrylic acid and a long chain alkyl methacrylate cross-linked with allyl ethers of pentaerythritol.
15 . The method of claim 13 , wherein the cyclosporin A is administered to the mammal before the mammal receives the therapeutically active agent.
16 . The method of claim 13 , wherein the cyclosporin A is administered to the mammal after the mammal begins to receive the therapeutically active agent.
17 . The method of claim 13 , wherein the cyclosporin A is administered to the mammal after the mammal ceases to receive the therapeutically active agent.
18 .- 22 . (canceled)